Lupin announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The Board of Directors approved these results on November 6, 2025. Key highlights include revenue from operations and profit before tax. The company also completed the transfer of its OTC and API R&D businesses to subsidiaries.
Financial Performance
Lupin reported a total income of ₹41,382.8 million for the quarter ended September 30, 2025, compared to ₹41,388.2 million for the same quarter last year. The profit before tax for the quarter stood at ₹16,358.1 million. The company’s total income for the six months ended September 30, 2025, was ₹99,010.1 million.
On a consolidated basis, the total revenue from operations for the quarter was ₹70,475.1 million, with profit before tax at ₹20,069.7 million.
Segmental Performance
The Pharmaceuticals segment reported revenue of ₹70,103.2 million for the quarter ended September 30, 2025. The segment’s profit before tax was ₹20,479.9 million. Total assets for the Pharmaceuticals segment reached ₹332,471.5 million.
Business Transfers
During the quarter, Lupin completed the transfer of its Over the Counter (OTC) and API R&D businesses in India to its wholly-owned subsidiaries, Lupinlife Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited, respectively. This was executed on a slump sale basis, resulting in a gain on divestment of ₹6,589.6 million and ₹37.2 million, respectively.
Dividend Disbursement
The company disbursed a final dividend of ₹12 per equity share on August 14, 2025, aggregating to ₹5,481.0 million.
Equity Allotment
The company allotted 41,745 equity shares due to the exercise of stock options under the Lupin Employees Stock Option Plans (ESOPs), increasing the paid-up equity share capital by ₹0.1 million.
Source: BSE
